Black Diamond Therapeutics, Inc.
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2020
- $0
- Net income
- $22.4M
- Total assets
- $143.0M
- Market cap
- $112.9M
- Operating margin
- 17.9%
- Net margin
- 32.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $70.0M
- Operating expenses
- $57.5M
- Operating income
- $12.5M
- Income tax
- $0
- Net income
- $22.4M
- EPS (basic)
- $0.39
- EPS (diluted)
- $0.39
Balance sheet
- Total assets
- $143.0M
- Current assets
- $132.4M
- Total liabilities
- $30.8M
- Current liabilities
- $15.7M
- Shareholders’ equity
- $112.2M
Cash flow
- Operating cash flow
- $29.6M
- Investing cash flow
- -$44.9M
- Financing cash flow
- -$146.0K
- Net cash flow
- -$15.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $112.9M
- P/E ratio
- 4.7
- EPS (diluted)
- $0.39
- Shares outstanding
- 61.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 30, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $22.4M in FY2020.
- Trading 62% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 4.7.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Black Diamond Therapeutics, Inc..
Write a review
News about Black Diamond Therapeutics, Inc.
News & sentiment via Polygon.io
